These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33482697)

  • 41. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
    Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
    Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
    Reardon DA; Turner S; Peters KB; Desjardins A; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Jones LW; Kirkpatrick JP; Friedman AH; Vredenburgh JJ; Bigner DD; Friedman HS
    J Natl Compr Canc Netw; 2011 Apr; 9(4):414-27. PubMed ID: 21464146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vessel co-option in glioblastoma: emerging insights and opportunities.
    Seano G; Jain RK
    Angiogenesis; 2020 Feb; 23(1):9-16. PubMed ID: 31679081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
    Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
    Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The glioblastoma vasculature as a target for cancer therapy.
    Dimberg A
    Biochem Soc Trans; 2014 Dec; 42(6):1647-52. PubMed ID: 25399584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.
    Zhang M; Ye G; Li J; Wang Y
    Brain Tumor Pathol; 2015 Oct; 32(4):229-36. PubMed ID: 26437643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes.
    Caspani EM; Crossley PH; Redondo-Garcia C; Martinez S
    PLoS One; 2014; 9(7):e101402. PubMed ID: 25032689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function.
    Wan B; Wu Z; Zhang X; Huang B
    Biochem Biophys Res Commun; 2021 Nov; 580():7-13. PubMed ID: 34607260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
    Dietrich J; Wang D; Batchelor TT
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1549-57. PubMed ID: 19671039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New molecular targets in angiogenic vessels of glioblastoma tumours.
    Anderson JC; McFarland BC; Gladson CL
    Expert Rev Mol Med; 2008 Aug; 10():e23. PubMed ID: 18684337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 59. Anti-angiogenic therapies in the management of glioblastoma.
    Schulte JD; Aghi MK; Taylor JW
    Chin Clin Oncol; 2021 Aug; 10(4):37. PubMed ID: 32389001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.